Human Genomics · 2023 · 25 citations · 23 references
MedicineGeneticsPharmacologyMedical GeneticsPharmacogeneticsPharmacogenomicsAtrial FibrillationGenetic RiskGenotype-phenotype Association AnalysisGenotype-phenotype CorrelationPharmacogenetic TestingPharmacogenomics In CardiologyBleedingCyp3a5 PharmacogeneticsCytochrome P450 Genotype EffectsDrug Trough ConcentrationPharmacogenomics Of Cardiovascular DrugsSteady-state Trough ConcentrationTrough Concentration AnalysisTrough Concentrations
Abstract Background The influence of genetic factors on the pharmacokinetics and clinical outcomes of rivaroxaban in patients with non-valvular atrial fibrillation (NVAF) is poorly understood. This study aimed to explore the effects of CYP3A4/5 , ABCB1 , and ABCG2 gene polymorphisms on the trough concentrations and the bleeding risk of rivaroxaban in NVAF patients. Patients and methods This study is a prospective multicenter study. The patient's blood samples were collected to detect the steady-state trough concentrations of rivaroxaban and gene polymorphisms. We visited the patients regularly at month 1, 3, 6, and 12 to record bleeding events and medications. Results A total of 95 patients were enrolled in this study, and 9 gene loci were detected. For the dose-adjusted trough concentration ratio (C trough /D) of rivaroxaban, the homozygous mutant type was significantly lower than wild type at ABCB1 rs4148738 locus (TT vs. CC, P = 0.033), and the mutant type was significantly lower than the wild type at ABCB1 rs4728709 locus (AA + GA vs. GG, P = 0.008). ABCB1 (rs1045642, rs1128503), CYP3A4 (rs2242480, rs4646437), CYP3A5 (rs776746), and ABCG2 (rs2231137, rs2231142) gene polymorphisms had no significant effect on the C trough /D of rivaroxaban. For the bleeding events, we found that there were no significant differences among genotypes of all gene loci. Conclusion This study found for the first time that ABCB1 rs4148738 and rs4728709 gene polymorphisms had a significant impact on the C trough /D of rivaroxaban in NVAF patients. CYP3A4/5 , ABCB1 , and ABCG2 gene polymorphisms were not associated with the bleeding risk of rivaroxaban.
23
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
Manesh R. Patel, Kenneth W. Mahaffey, Jyotsna Garg et al. · New England Journal of Medicine · 2011 · 9.4K citations · Full text
Dagmar Kubitza, Michael Becka, Wolfgang Mueck et al. · British Journal of Clinical Pharmacology · 2010 · 431 citations · Full text
Marianne K. DeGorter, Rommel G. Tirona, Ute I. Schwarz et al. · Circulation Cardiovascular Genetics · 2013 · 192 citations · Full text